This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
West Pharmaceutical Services (WST) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) Q3 Earnings Top Estimates, View Up
by Zacks Equity Research
Quest Diagnostics (DGX) notes that in late summer it experienced some softness in the base business across the country but recovered in September.
What's in Store for West Pharmaceutical's (WST) Q3 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business.
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Continued strong adoption of Invisalign Clear Aligners and iTero scanners is expected to contribute to Align Technology's (ALGN) third-quarter 2021 results.
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Insulet's (PODD) Omnipod Sales Grow on New Product Upgrade
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.
Abbott's (ABT) Q3 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Abbott's (ABT) COVID-19 testing-related sales in Q3 increase on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.
QIAGEN (QGEN) New Launch to Aid Global TB Elimination Targets
by Zacks Equity Research
QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.
Intuitive Surgical's (ISRG) Ion System Backed by Clinical Study
by Zacks Equity Research
Latest study results of Intuitive Surgical's (ISRG) Ion system indicate the potential for this technology to help safely biopsy small lung nodules.
Abbott's (ABT) Nutrition Arm in Focus on Real Madrid Alliance
by Zacks Equity Research
According to Abbott (ABT), the partnership is set to support education, sports and social welfare activities of at-risk children in 80 countries.
Here's Why You Should Retain Allscripts (MDRX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and various innovation milestones.
LHC Group (LHCG) Reports Impressive Preliminary Q3 Revenues
by Zacks Equity Research
Growth in LHC Group's (LHCG) revenues in the third quarter is likely to have been boosted by continued strength in its home health and hospice services.
PerkinElmer's (PKI) New Deal to Improve Single-Cell Profiling
by Zacks Equity Research
PerkinElmer (PKI) partners with Honeycomb Biotechnologies to launch HIVE scRNAseq Solution, which can advance single-cell profiling.
Charles River (CRL) to Offer Cryo-EM Capabilities With New Pact
by Zacks Equity Research
Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and raised 2021 earnings guidance.
NuVasive (NUVA) Announces Two Developments in Cohere TLIF Line
by Zacks Equity Research
According to NuVasive (NUVA), Porous PEEK is a clear differentiator for the company in the market.
Hologic (HOLX) to Expand Surgical Portfolio With Bolder Buyout
by Zacks Equity Research
Hologic's (HOLX) recent acquisition will accelerate its growth and enhance patient outcomes by leveraging significant commercial resources and strong relationships with OB/GYN specialists.
3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.
Cardinal Health's (CAH) Unit Ties Up to Boost Diabetes Care
by Zacks Equity Research
Cardinal Health's (CAH) company, OptiFreight Logistics', recent collaboration with Journey Biosciences to help patients with respect to long-term diabetes care.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Allscripts' (MDRX) New AI-Based Offering to Improve Patient Care
by Zacks Equity Research
Allscripts' (MDRX) latest AI-based scheduling application is expected to provide improved patient care as well as increase operational efficiencies of the healthcare system.
Walgreens Boots (WBA) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Walgreens Boots' (WBA) health and wellness sales increase for fiscal Q4 on growing demand for at-home COVID-19 tests and vitamins.
Quest Diagnostics (DGX) Enhances Lab Experience With Facility
by Zacks Equity Research
Quest Diagnostics (DGX) new facility is fully operational and will empower better health for the patients and clients in the seven states the lab serves.
Edwards Lifesciences (EW) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Improvement in Critical Care and Surgical Structural Heart businesses is expected to have contributed to Edwards Lifesciences' (EW) third-quarter results.